MDMA and prosocial behavior.

Gepubliceerd: 03-12-2010 Laatst bijgewerkt: 15-05-2024

1. Oxytocin will mimic MDMA-induced prosocial effects; 2. Blockade of the 5-HT1A receptor will prevent occurrence prosocial effects after MDMA intake (acute, not on subsequent occasions); 3. MDMA users carrying the fast working SERT genotype...

Ethische beoordeling	Niet van toepassing
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON26647

Bron
Nationaal Trial Register

Verkorte titel
MDMA & PSB

Aandoening

prosocial behavior, oxytocin, 5-HT1a receptor, MDMA

Ondersteuning

Primaire sponsor: Dr. Kim Kuypers,
Dept. of NP & PP, Fac of FPN, UM
P.O.Box 616
6200 MD Maastricht
tel: +31433881902
fax: +31433884560
email: k.kuypers@maastrichtuniversity.nl
Overige ondersteuning: Netherlands Organisation for Scientific Research (NWO)

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

1. Dependent variables of the empathy and social interaction tasks, measured with computertasks;
2. Treatment concentrations and oxytocin concentrations in the blood (bloodsample).

Toelichting onderzoek

Achtergrond van het onderzoek

The aim of the present study is to investigate the roles of oxytocin and the 5-HT1A receptor in MDMA-induced prosocial effects. Eighteen participants will go through four treatment conditions on four occasions, separated by a minimum of 7 days washout. Social behavior and mood will be assessed in the laboratory. It is hypothesized that oxytocin will mimic MDMA-induced prosocial effects and that the 5-HT1A receptor is an important mediator of these effects.

Doel van het onderzoek

1. Oxytocin will mimic MDMA-induced prosocial effects;

2. Blockade of the 5-HT1A receptor will prevent occurrence prosocial effects after MDMA intake (acute, not on subsequent occasions);

3. MDMA users carrying the fast working SERT genotype variant (LaLa) will experience more pronounced prosocial effects compared with the users carrying the slow working variant.

Onderzoeksopzet

1. Medical screening;

2. Training of the computer tasks;

3. 4 testdays seperated by a minimum of 7 days washout.

Total study burden= 18,5 hours, spread over minimally 5 weeks.

Onderzoeksproduct en/of interventie

Administration of treatments* and collection of a blood sample each test day to determine treament concentrations and oxytocin concentrations in the blood.

*There are 4 treatment conditions and these willl be:

1. A single dose of MDMA (75mg);

2. Syntocinon (32 international units);

3. MDMA (75 mg) combined with Visken (20 mg);

4. Placebo.

Contactpersonen

Publiek

P.O. Box 616

K.P.C. Kuypers
Universiteit Maastricht, Fac. FPN. Dept. NP&PP, PB 616
Maastricht 6200 MD
The Netherlands
+31 (0)433881902

Wetenschappelijk

P.O. Box 616

K.P.C. Kuypers
Universiteit Maastricht, Fac. FPN. Dept. NP&PP, PB 616
Maastricht 6200 MD
The Netherlands
+31 (0)433881902

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Experience with the use of MDMA (maximally 100 times in total, minimally 2 times in total; and at least once in the past 12 months);

2. Age between 18-40 years;

3. Free from medication (except oral contraception);

4. Good physical health as determined by examination and laboratory analysis;

5. Absence of any major medical, endocrine and neurological condition;

6. Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2;

7. Written Informed Consent;

8. Native Dutch speaker (as some tasks require this).

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. History of drug abuse (other than the use of MDMA) or addiction;

2. Women: Pregnancy or lactation;

3. Cardiovascular abnormalities as assessed by standard 12-lead ECG;

4. Excessive drinking (> 20 alcoholic consumptions a week);

5. Hypertension (diastolic> 100; systolic> 170);

6. Current or history of psychiatric disorder.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek

Onderzoeksmodel:	Cross-over
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind
Controle:	Placebo

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-02-2011
Aantal proefpersonen:	18
Type:	Verwachte startdatum

Ethische beoordeling

Niet van toepassing

Soort:	Niet van toepassing

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 36227
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL2518
NTR-old	NTR2636
CCMO	NL34859.068.10
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON36227

Resultaten

Samenvatting resultaten
N/A